Fig. 2.
Heterogeneity of PDAC. Transcriptomic analysis is able to classify PDAC into phenotypic subtypes, from classical (well differentiated) to basal (poorly differentiated) phenotypes. Several RNAs have been defined as specific markers. These phenotypes are associated with very distinct clinical evolutions. The clinical outcome of a new PDAC can be defined by obtaining its transcriptome and analyzing it to classify the PDAC as a classical, intermediate, or basal tumor.